Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Allow: / Disallow: /pdf/Social-Media-Community-Guidelines.pdf Sitemap: |
Title | MONJUVI® (tafasitamab-cxix) 200mg: Treatment for R/R DLBCL | Official Patient |
Description | See how MONJUVI may help if your DLBCL came back or did not respond to the first MONJUVI® (tafasitamab-cxix) for relapsed/refractory (R/R) DLBCL is a 200mg injection for intravenous use. Download the Dr. Discussion Guide. Please see the full Prescribing Information including Patient Information for additional Important Safety |
Keywords | N/A |
WebSite | monjuvi.com |
Host IP | 40.71.11.143 |
Location | United States |
Site | Rank |
US$16,147,655
Last updated: 2023-04-28 00:34:52
monjuvi.com has Semrush global rank of 655,470. monjuvi.com has an estimated worth of US$ 16,147,655, based on its estimated Ads revenue. monjuvi.com receives approximately 1,863,191 unique visitors each day. Its web server is located in United States, with IP address 40.71.11.143. According to SiteAdvisor, monjuvi.com is safe to visit. |
Purchase/Sale Value | US$16,147,655 |
Daily Ads Revenue | US$14,906 |
Monthly Ads Revenue | US$447,166 |
Yearly Ads Revenue | US$5,365,990 |
Daily Unique Visitors | 124,213 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
monjuvi.com. | A | 599 | IP: 40.71.11.143 |
monjuvi.com. | NS | 86400 | NS Record: ns.udag.net. |
monjuvi.com. | NS | 86400 | NS Record: ns.udag.org. |
monjuvi.com. | NS | 86400 | NS Record: ns.udag.de. |
monjuvi.com. | MX | 3600 | MX Record: 20 mx02.morphosys.com. |
monjuvi.com. | MX | 3600 | MX Record: 10 mx01.morphosys.com. |
monjuvi.com. | TXT | 600 | TXT Record: D497572210F3181359685E7EA3615D5F2713BDBE95F7918D987A0E2924C60142 |
What is MONJUVI? What is MONJUVI? MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant. It is not known if MONJUVI is safe and effective in children. The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI. Intended for US residents only MONJUVI Prescribing Information US Healthcare Professionals Site My MISSION Support Program Menu About MONJUVI Starting MONJUVI Treatment Tracker Treatment Considerations For Caregivers Support & Resources FAQs MONJUVI Prescribing Information US Healthcare Professionals Site My MISSION Support Program See how MONJUVI may help if your DLBCL came back or did not respond to the first treatment ABOUT MONJUVI Not an actual patient. DLBCL=diffuse large |
HTTP/1.1 301 Moved Permanently Content-Length: 0 Content-Type: text/html; charset=UTF-8 Location: https://monjuvi.com/ Date: Thu, 21 Oct 2021 03:31:33 GMT HTTP/2 301 content-length: 0 content-type: text/html; charset=iso-8859-1 location: https://www.monjuvi.com/ server: Apache/2.4.25 (Debian) date: Thu, 21 Oct 2021 03:31:32 GMT HTTP/2 200 content-length: 0 content-type: text/html; charset=UTF-8 server: Apache/2.4.25 (Debian) x-powered-by: PHP/7.2.2 date: Thu, 21 Oct 2021 03:31:33 GMT |
Domain Name: MONJUVI.COM Registry Domain ID: 2257850897_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.udag.net Registrar URL: http://www.united-domains.de Updated Date: 2021-07-29T15:36:18Z Creation Date: 2018-04-28T18:06:41Z Registry Expiry Date: 2022-04-28T18:06:41Z Registrar: United-Domains AG Registrar IANA ID: 1408 Registrar Abuse Contact Email: abuse@united-domains.de Registrar Abuse Contact Phone: +49.8151368670 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS.UDAG.DE Name Server: NS.UDAG.NET Name Server: NS.UDAG.ORG DNSSEC: unsigned >>> Last update of whois database: 2021-09-09T19:54:20Z <<< |